Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Medical Microbiology and Immunology
Published in: Medical Microbiology and Immunology 2/2008

01-06-2008 | Review

Human cytomegalovirus infection and antiviral immunity in septic patients without canonical immunosuppression

Authors: Lutz von Müller, Thomas Mertens

Published in: Medical Microbiology and Immunology | Issue 2/2008

Login to get access

Abstract

The human cytomegalovirus (HCMV) is a relevant pathogen in patients with immunosuppressive therapy; however, reactivation and subsequent recurrence occurs also in individuals without canonical immunosuppression as e.g., in patients with septic shock. Analyzing the impact of NK- and T-cell immunity on the natural course of HCMV infection in patients with septic shock, it became clear that the presence of HCMV reactive T-helper cells did not prevent the development of reactivation but, the control of active infection was achieved mostly by specific T-cells. NK-cells seemed to be dispensable for clearance of active infection in this patient group with long-lasting NK-cell anergy.
Literature
1.
Stagno S, Britt W (2006) Cytomegalovirus infections. In: Remington JS, Klein JO, Wilson CB, Baker CJ (eds) Infectious diseases of the fetus and newborn infant, 6th edn. Elsevier Saunders, Philadelphia, pp 739–781CrossRef
2.
Griffiths PD (2002) Tomorrow’s challenges for herpesvirus management: potential applications of valacyclovir. J Infect Dis 186(Suppl 1):S131–S137PubMedCrossRef
3.
Ljungman P, Griffiths P, Paya C (2002) Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 34:1094–1097PubMedCrossRef
4.
Sinclair J, Sissons P (2006) Latency and reactivation of human cytomegalovirus. J Gen Virol 87:1763–1779PubMedCrossRef
5.
Hummel M, Abecassis MM (2002) A model for reactivation of CMV from latency. J Clin Virol 25(Suppl 2):S123–S136PubMedCrossRef
6.
Simon CO, Seckert CK, Dreis D, Reddehase MJ, Grzimek NK (2005) Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs. J Virol 79:326–340PubMedPubMedCentralCrossRef
7.
8.
von Müller L, Klemm A, Weiss M, Schneider M, Suger-Wiedeck H, Durmus N, Hampl W, Mertens T (2006) Active cytomegalovirus infection in patients with septic shock. Emerg Infect Dis 12:1517–1522CrossRef
9.
Heininger A, Jahn G, Engel C, Notheisen T, Unertl K, Hamprecht K (2001) Human cytomegalovirus infections in nonimmunosuppressed critically ill patients. Crit Care Med 29:541–547PubMedCrossRef
10.
Kutza AST, Muhl E, Hackstein H, Kirchner H, Bein G (1998) High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis 26:1076–1082PubMedCrossRef
11.
Limaye AP, Kirby KA, Rubenfeld GD, Huang ML, Santo TK, Corey L, Boeckh M (2007) Association of cytomegalovirus (CMV) viral load with intensive care unit and hospital length of stay in critically-ill immunocompetent patients. Abstract #406, American Thoracic Society international Conference
12.
Mocarski ES, Shenk T, Pass RF (2007) Cytomegalovirus. In: Knipe DM, Howley PM (eds) Fields virology, 5th edn. Lippincott-Raven, Philadelphia, pp 2701–2772
13.
von Müller L, Klemm A, Durmus N, Weiss M, Suger-Wiedeck H, Schneider M, Hampl W, Mertens T (2007) Cellular immunity and active human cytomegalovirus infection in patients with septic shock. J Infect Dis 196:1288–1295CrossRef
14.
Frascaroli G, Varani S, Mastroianni A, Britton S, Gibellini D, Rossini G, Landini MP, Soderberg-Naucler C (2006) Dendritic cell function in cytomegalovirus-infected patients with mononucleosis. J Leukoc Biol 79:932–940PubMedCrossRef
15.
Ljungman P, Reusser P, de la CR, Einsele H, Engelhard D, Ribaud P, Ward K (2004) Management of CMV infections: recommendations from the infectious diseases working party of the EBMT. Bone Marrow Transplant 33:1075–1081PubMedCrossRef
16.
Barrios Y, Knor S, Lantto J, Mach M, Ohlin M (2007) Clonal repertoire diversification of a neutralizing cytomegalovirus glycoprotein B-specific antibody results in variants with diverse anti-viral properties. Mol Immunol 44:680–690PubMedCrossRef
17.
Nigro G, Adler SP, La TR, Best AM (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350–1362PubMedCrossRef
18.
Klenovsek K, Weisel F, Schneider A, Appelt U, Jonjic S, Messerle M, Bradel-Tretheway B, Winkler TH, Mach M (2007) Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 110:3472–3479PubMedCrossRef
19.
Reddehase MJ, Jonjic S, Weiland F, Mutter W, Koszinowski UH (1988) Adoptive immunotherapy of murine cytomegalovirus adrenalitis in the immunocompromised host: CD4-helper-independent antiviral function of CD8-positive memory T lymphocytes derived from latently infected donors. J Virol 62:1061–1065PubMedPubMedCentralCrossRef
20.
Hertenstein B, Hampl W, Bunjes D, Wiesneth M, Duncker C, Koszinowski U, Heimpel H, Arnold R, Mertens Th (1995) In vivo/ex vivo T cell depletion for GVHD prophylaxis influences onset and course of active cytomegalovirus infection and disease after BMT. Bone Marrow Transplant 15:387–393PubMed
21.
Cerboni C, Mousavi-Jazi M, Linde A, Söderström K, Brytting M, Wahren B, Kärre K, Carbone E (2000) Human cytomegalovirus strain-dependent changes in NK cell recognition of infected fibroblasts. J Immunol 164:4775–4782PubMedCrossRef
22.
Reddehase MJ, Balthesen M, Rapp M, Jonjic S, Pavic I, Koszinowski UH (1994) The conditions of primary infection define the load of latent viral genome in organs and the risk of recurrent cytomegalovirus disease. J Exp Med 179:185–193PubMedCrossRef
23.
24.
Steffens H-P, Kurz S, Holtappels R, Reddehase MJ (1998) Preemptive CD8 T-cell immunotherapy of acute cytomegalovirus infection prevents lethal disease, limits the burden of latent viral genomes, and reduces the risk of virus recurrence. J Virol 72:1797–1804PubMedPubMedCentralCrossRef
25.
Hummel M, Zhang Z, Yan S, DePlaen I, Golia P, Varghese T, Thomas G, Abecassis MI (2001) Allogeneic transplantation induces expression of cytomegalovirus immediate-early genes in vivo: a model for reactivation from latency. J Virol 75:4814–4822PubMedPubMedCentralCrossRef
26.
Cook CH, Zhang Y, McGuinness BJ, Lahm MC, Sedmak DD, Ferguson RM (2002) Intra-abdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice. J Infect Dis 185:1395–1400PubMedCrossRef
27.
Cook CH, Trgovcich J, Zimmerman PD, Zhang Y, Sedmak DD (2006) Lipopolysaccharide, tumor necrosis factor alpha, or interleukin-1beta triggers reactivation of latent cytomegalovirus in immunocompetent mice. J Virol 80:9151–9158PubMedPubMedCentralCrossRef
28.
von Müller L, Schliep C, Storck M, Hampl W, Schmid T, Abendroth D, Mertens T (2006) Severe graft rejection, increased immunosuppression, and active CMV infection in renal transplantation. J Med Virol 78:394–399CrossRef
29.
Reeves MB, MacAry PA, Lehner PJ, Sissons JG, Sinclair JH (2005) Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc Natl Acad Sci USA 102:4140–4145PubMedPubMedCentralCrossRef
30.
Reeves MB, Coleman H, Chadderton J, Goddard M, Sissons JG, Sinclair JH (2004) Vascular endothelial and smooth muscle cells are unlikely to be major sites of latency of human cytomegalovirus in vivo. J Gen Virol 85:3337–3341PubMedCrossRef
31.
Mocarski ES (2002) Immunomodulation by cytomegaloviruses: manipulative strategies beyond evasion. Trends Microbiol 10:332–339PubMedCrossRef
32.
Soderberg-Naucler C, Fish KN, Nelson JA (1997) Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 91:119–126PubMedCrossRef
33.
Rennekampff HO, Hamprecht K (2006) Cytomegalovirus infection in burns: a review. J Med Microbiol 55:483–487PubMedCrossRef
34.
Sester M, Gartner BC, Sester U, Girndt M, Mueller-Lantzsch N, Kohler H (2003) Is the cytomegalovirus serologic status always accurate? a comparative analysis of humoral and cellular immunity. Transplantation 76:1229–1230PubMedCrossRef
35.
von Müller L, Hinz J, Bommer M, Hampl W, Kluwick S, Wiedmann M, Bunjes D, Mertens T (2007) CMV monitoring using blood cells and plasma: a comparison of apples with oranges? Bone Marrow Transplant 39:353–357CrossRef
36.
Emery VC, Sabin CA, Cope AV, Gor D, Hassan-Walker AF, Griffiths PD (2000) Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 355:2032–2036PubMedCrossRef
37.
Einsele H, Roosnek E, Rufer N, Sinzger C, Riegler S, Loffler J, Grigoleit U, Moris A, Rammensee HG, Kanz L et al (2002) Infusion of cytomegalovirus (CMV)-specific T cells for the treatment of CMV infection not responding to antiviral chemotherapy. Blood 99:3916–3922PubMedCrossRef
38.
39.
Rauser G, Einsele H, Sinzger C, Wernet D, Kuntz G, Assenmacher M, Campbell JD, Topp MS (2004) Rapid generation of combined CMV-specific CD4+ and CD8+ T-cell lines for adoptive transfer into recipients of allogeneic stem cell transplants. Blood 103:3565–3572PubMedCrossRef
40.
Riddell SR, Watanabe KS, Goodrich JM, Li CR, Agha ME, Greenberg PD (1992) Restoration of viral immunity in immunodeficient humans by the adoptive transfer of T cell clones. Science 257:238–241PubMedCrossRef
41.
Mocarski ES (2004) Immune escape and exploitation strategies of cytomegaloviruses: impact on and imitation of the major histocompatibility system. Cell Microbiol 6:707–717PubMedCrossRef
42.
French AR, Yokoyama WM (2003) Natural killer cells and viral infections. Curr Opin Immunol 15:45–51PubMedCrossRef
43.
Puente J, Carvajal T, Parra S, Miranda D, Sepulveda C, Wolf ME, Mosnaim AD (1993) In vitro studies of natural killer cell activity in septic shock patients. Response to a challenge with alpha-interferon and interleukin-2. Int J Clin Pharmacol Ther Toxicol 31:271–275PubMed
44.
Vredevoe DL, Widawski M, Fonarow GC, Hamilton M, Martinez-Maza O, Gage JR (2004) Interleukin-6 (IL-6) expression and natural killer (NK) cell dysfunction and anergy in heart failure. Am J Cardiol 93:1007–1011PubMedCrossRef
45.
Waner JL, Budnick JE (1977) Blastogenic response of human lymphocytes to human cytomegalovirus. Clin Exp Immunol 30:44–49PubMedPubMedCentral
46.
Sester M, Sester U, Gärtner B, Heine G, Girndt M, Mueller-Lantzsch N, Meyerhans A, Kohler H (2001) Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation. Transplantation 71:1287–1294PubMedCrossRef
47.
Llewelyn M, Cohen J (2002) Superantigens: microbial agents that corrupt immunity. Lancet Infect Dis 2:156–162PubMedCrossRef
48.
Ljungman P, De Bock R, Cordonnier C, Einsele H, Engelhard D, Grundy J, Locasciulli A, Reusser P, Ribaud P (1993) Practices for cytomegalovirus diagnosis, prophylaxis and treatment in allogeneic bone marrow transplant recipients: a report from the working party for infectious diseases of the EBMT. Bone Marrow Transplant 12:399–403PubMed
49.
Barry SM, Johnson MA, Janossy G (2000) Cytopathology or immunopathology? The puzzle of cytomegalovirus pneumonitis revisited. Bone Marrow Transplant 26:591–597PubMedPubMedCentralCrossRef
50.
Fishman JA, Emery V, Freeman R, Pascual M, Rostaing L, Schlitt HJ, Sgarabotto D, Torre-Cisneros J, Uknis ME (2007) Cytomegalovirus in transplantation—challenging the status quo. Clin Transplant 21:149–158PubMedCrossRef
51.
Lowance D, Neumayer H-H, Legendre CM, Squifflet J-P, Kovarik J, Brennan PJ, Norman D, Mendez R, Keating MR, Coggon GL et al (1999) Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. N Engl J Med 340:1462–1470PubMedCrossRef
52.
Reinhardt B, Mertens Th, Mayr U, Frank H, Lüske A, Waltenberger J (2004) HCMV-infection leads to enhanced PDGF responsiveness of vascular smooth muscle cells. Cardiovasc Res
53.
Cook CH, Zhang Y, Sedmak DD, Martin LC, Jewell S, Ferguson RM (2006) Pulmonary cytomegalovirus reactivation causes pathology in immunocompetent mice. Crit Care Med 34:842–849PubMedPubMedCentralCrossRef
54.
Docke WD, Prosch S, Fietze E, Kimel V, Zuckermann H, Klug C, Syrbe U, Kruger DH, von Baehr R, Volk HD (1994) Cytomegalovirus reactivation and tumour necrosis factor. Lancet 343:268–269PubMedCrossRef
55.
Simon CO, Holtappels R, Tervo HM, Bohm V, Daubner T, Oehrlein-Karpi SA, Kuhnapfel B, Renzaho A, Strand D, Podlech J et al (2006) CD8 T cells control cytomegalovirus latency by epitope-specific sensing of transcriptional reactivation. J Virol 80:10436–10456PubMedPubMedCentralCrossRef
Metadata
Title
Human cytomegalovirus infection and antiviral immunity in septic patients without canonical immunosuppression
Authors
Lutz von Müller
Thomas Mertens
Publication date
01-06-2008
Publisher
Springer Berlin Heidelberg
Published in
Medical Microbiology and Immunology / Issue 2/2008
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI
https://doi.org/10.1007/s00430-008-0087-0

Other articles of this Issue 2/2008

Medical Microbiology and Immunology 2/2008 Go to the issue

Review

CD8 T-cell-based immunotherapy of cytomegalovirus infection: “proof of concept” provided by the murine model

Review

Phenotypes of major immediate-early gene mutants of mouse cytomegalovirus

Original Investigation

Evaluation of recombinant modified vaccinia Ankara virus-based rhesus cytomegalovirus vaccines in rhesus macaques

Review

Conditional gene expression systems to study herpesvirus biology in vivo

Review

Murine cytomegalovirus regulation of NKG2D ligands

Review

Correlation of dendritic cell maturation and the formation of aggregates of poly-ubiquitinated proteins in the cytosol
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits